This CIRS multi-stakeholder workshop examined strategies for incentivising the development of medicines for common chronic diseases.
CIRS authors write about benefit-risk in the March 2010 issue of Regulatory Focus by the Regulatory Affairs Professionals Society (RAPS). Article reproduced with the permission of RAPS. Download [...]
Review and reimbursement: A special case for better co-operation 29-30th September 2009, Surrey, UK The current dynamics of bringing new medicines to market are influenced by potential conflicts between [...]
Strategies for communicating benefits and risks to decision makers: Explaining methods, findings and conclusions through a common language approach 17-19th June 2009, Washington DC, USA Determining the benefit-risk (BR) [...]
Expediting patients' access to medicines: Solutions to simultaneous submissions and approvals 20-31 March 2009, Surrey, UK Major companies engaging in global development programmes are currently trying to reduce the [...]
Predictable outcomes: Why do potential winners fail? 30th September - 1st October 2008, Washington DC, USA A little more than 10% of new compounds that are at the first-human-dose [...]
Clinical development in Asia, Africa and Latin America: Streamlining the procedure for obtaining global clinical trial approvals 1st-2nd December 2008, Intercontinental Hotel, Singapore Is the concept of the simultaneous [...]
Measuring benefit and balancing risk: Strategies for the benefit-risk assessment of new medicines in a risk-averse environment 19-20th June 2008, Sofitel Lafayette Square, Washington DC, USA Measuring the benefits [...]
Knowledge sharing and co-operation - Are these the key to a more certain future for pharmaceutical innovation? 29-30th April 2008, Surrey, UK Altruism or enlightened self-interest – what are [...]
Regulation and reimbursement - Two sides of the same coin? 16-17th January 2008, Surrey, UK Background The topic for this Workshop, held in Surrey, UK, January 2008, was a [...]
